Poster Presentation Scheduled for December 6, 2015
TORRANCE, Calif., December 2, 2015 – Emmaus Life Sciences, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies for rare and orphan diseases, today announced that it will present new data from the Company’s Phase 3 clinical trial of its oral pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell anemia and sickle beta-0 thalassemia, at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition on December 6, 2015 in Orlando, Florida.
Additional analyses on the data from the Company’s Phase 3 trial demonstrated a reduction in severity of painful crisis. The additional data further builds upon clinical benefits observed in the Phase 3 PGLG trial, including a reduction in the median frequency of sickle cell crisis, a lower median frequency of hospitalizations, a reduction in median cumulative hospital days, and fewer cases of acute chest syndrome.
“We are pleased this additional data helps document that PGLG may be providing clinical benefit by reducing the severity of painful crises observed in the trial,” said Yutaka Niihara, M.D., MPH, Chairman of Emmaus.
Poster Presentation Details:
Title: “Decrease in the Severity of Painful Sickle Cell Crises with Oral PGLG”
When: Sunday, December 6, 2015, 6:00 PM-8:00 PM EST
Where: Hall A, Level 2 (Orange County Convention Center)
About Emmaus Life Sciences
Emmaus Life Sciences is engaged in the discovery, development and commercialization of innovative treatments and therapies for rare diseases. The Company’s research on sickle cell disease was initiated by Dr. Niihara at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Emmaus’ SCD therapy has Orphan Drug designation in the U.S. and Europe and Fast Track designation from the FDA.
For more information, please visit www.emmauslifesciences.com.
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and potential commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. Additional risks and uncertainties are described in reports filed by Emmaus Life Sciences, Inc. with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Emmaus is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
Lori Teranishi for Emmaus Life Sciences, Inc.
Matt Sheldon for Emmaus Life Sciences, Inc.